# A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

> **NCT00358930** · PHASE2 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 60 (—)

## Conditions studied

- Head and Neck Neoplasms
- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** ARQ 501

## Key facts

- **NCT ID:** NCT00358930
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 60 (—)
- **Last updated:** 2009-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358930, "A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00358930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*